Mannkind (MNKD) Cash from Financing Activities (2010 - 2026)
Mannkind's (MNKD) quarterly Cash from Financing Activities came in at -$35.4 million in Q1 2026, down 2647.19% year-on-year from $1.4 million in Q1 2025, and down 114.31% on a QoQ basis from $247.4 million in Q4 2025.
Mannkind (MNKD) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has 17 years of Cash from Financing Activities data on file, last reported at -$35.4 million in Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 2647.19% year-over-year to -$35.4 million in Q1 2026; TTM through Mar 2026 was $278.3 million, a 310.2% increase from a year earlier, with the FY2025 full-year figure at $315.1 million, up 329.55% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$35.4 million, down from $247.4 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for MNKD reached as high as $247.4 million in Q4 2025 and fell as low as -$86.9 million in Q4 2024.
- Historically, Cash from Financing Activities has averaged $17.7 million across 5 years, with a median of -$283000.0 in 2023.
- Across the five-year window, Cash from Financing Activities surged 4915.26% in 2023 and slumped 2647.19% in 2026, its largest moves.
- Year by year, Cash from Financing Activities stood at $2.8 million in 2022, then jumped by 4915.26% to $141.7 million in 2023, then sank by 161.33% to -$86.9 million in 2024, then soared by 384.71% to $247.4 million in 2025, then sank by 114.31% to -$35.4 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$35.4 million in Q1 2026, $247.4 million in Q4 2025, and $71.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Mannkind | 1.20 Bn | 1.07 Bn | 82.66 Mn | -35.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.41 Mn |
| Mar 31, 2026 | -35.41 Mn |
| Dec 31, 2025 | 247.41 Mn |
| Dec 31, 2025 | 247.41 Mn |
| Sep 30, 2025 | 71.81 Mn |
| Sep 30, 2025 | 71.81 Mn |
| Jun 30, 2025 | -5.51 Mn |
| Jun 30, 2025 | -5.51 Mn |
| Mar 31, 2025 | 1.39 Mn |
| Mar 31, 2025 | 1.39 Mn |
| Dec 31, 2024 | -86.90 Mn |
| Dec 31, 2024 | -86.90 Mn |
| Sep 30, 2024 | -2.34 Mn |
| Sep 30, 2024 | -2.34 Mn |
| Jun 30, 2024 | -44.55 Mn |
| Jun 30, 2024 | -44.55 Mn |
| Mar 31, 2024 | -3.47 Mn |
| Mar 31, 2024 | -3.47 Mn |
| Dec 31, 2023 | 141.68 Mn |
| Dec 31, 2023 | 141.68 Mn |